Isolation of human umbilical cord blood-derived osteoprogenitor cells: a promising candidate for cell-based therapy for bone repair

Objective: The aim of this study was to evaluate the osteogenic potential of human umbilical cord blood-derived osteoprogenitor cells and to prove its applicability as a promising candidate for cell-based therapeutics for bone repair. Methods: Primary cultures of human umbilical blood cord adherent...

Full description

Saved in:
Bibliographic Details
Published inEinstein (São Paulo, Brazil) Vol. 9; no. 4; pp. 449 - 455
Main Authors Igor Iuco Castro-Silva, Letícia de Oliveira Castro, Janaína José dos Santos Machado, Maria Helena Alves Nicola, José Mauro Granjeiro
Format Journal Article
LanguageEnglish
Published Instituto Israelita de Ensino e Pesquisa Albert Einstein 01.12.2011
Subjects
Bone regeneration
Cell culture
Fetal blood
Osteogenesis
Tissue therapy
Umbilical cord
Online AccessGet full text

Cover

More Information
Summary:Objective: The aim of this study was to evaluate the osteogenic potential of human umbilical cord blood-derived osteoprogenitor cells and to prove its applicability as a promising candidate for cell-based therapeutics for bone repair. Methods: Primary cultures of human umbilical blood cord adherent cells were expanded in vitro until passage 2 and seeded for osteodifferentiation study. Morphological (light microscopy), cytochemical (Von Kossa’s method), and functional analyses (calcium level, alkaline phosphatase activity, and total protein content in cell culture) were carried out 7, 14, 21, and 28 days after the osteoinduction protocol. Results: The proliferative step showed colony-forming units in 7 days. After osteoinduction, cuboidal cellular morphology similar to osteoblasts at 14 days and mineralization nodules and biochemical changes (increased alkaline phosphatase level and calcium deposits) at 21 days confirmed the osteodifferentiation process. Conclusion: Cell culture of human umbilical blood cord is a reliable technique, constituting itself as an alternative source of osteoprogenitor cells for experimental needs. More animal tests and clinical trials must be carried out to validate its use and to establish quality control of future autologous or allogeneic cell-based therapy aimed at bone repair.
ISSN:1679-4508